|Bid||64.85 x 900|
|Ask||64.90 x 1100|
|Day's range||63.30 - 64.75|
|52-week range||56.56 - 85.97|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||659.39|
|Earnings date||28 Apr 2021 - 03 May 2021|
|Forward dividend & yield||2.84 (4.39%)|
|Ex-dividend date||12 Mar 2021|
|1y target est||74.54|
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vir Biotechnolgy (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) recently expanded their partnership from a single drug to treat COVID-19 to a multi-drug partnership that covers a drug for the flu, as well as drugs that Vir hasn't even developed yet.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new, long-term data from open-label extensions (OLE) of two Phase 3 studies (Study 1489 and Study 1490) of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF), demonstrating the sustained efficacy and safety profile and no treatment-emergent resistance with Biktarvy for the treatment of HIV-1 in treatment-naïve adults. The data were presented at the 28th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2021).